Dallas Conference

March 24-25, 2017

Welcome/Introduction• Mack Mitchell, MD, and Lawrence R. Schiller, MD

Emerging hepatitis C (HCV) therapies-2017/2018• Fred Poordad, MD

Complications of cirrhosis: hepatic encephalopathy, ascites and variceal bleeding• Kimberly Brown, MD

Does curing HCV lead to HBV reactivation and higher risk of hepatocellular carcinoma (HCC)?• Jordan Feld, MD

HCC: Update on role of metabolic syndrome, screening and treatment• Hashem El-serag, MD, MPH

Q&A/Panel Discussion•

Advances in opioid-induced constipation management• Brooks Cash, MD

Fecal incontinence: Sealing the leak• Satish Rao, MD

Diarrhea: Managing exocrine pancreatic insufficiency (EPI), irritable bowel syndrome (IBS)
and small bowel bacterial overgrowth (SIBO)• Lawrence R. Schiller, MD

Q&A/Panel Discussion•

Diagnosis and management of primary biliary cholangitis (PBC)• Kris Kowdley, MD

Advances in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)• Naim Alkhouri, MD

Management of drug-induced liver injury (DILI)• Mack Mitchell, MD

Q&A/Panel Discussion•

Gastroparesis 2017-There is effective therapy and prevention is at hand• Richard McCallum, MD

Endoscopy in obesity: balloons and other devices• Shelby Sullivan, MD

Barrett's esophagus and esophageal cancer-Why can't we have more of an impact?• Joel Richter, MD

Q&A/Panel Discussion•

Management of celiac disease• Joseph Murray, MD

Preparing for the expanded use of biosimilars in inflammatory bowel disease (IBD)• Thomas Ullman, MD

Should chromoendoscopy be the standard for surveillance of colitis?• Themistocles Dassopoulos, MD

Q&A/Panel Discussion•

Cleveland Conference

June 3-4, 2016

Dallas Conference

April 8 - 9, 2016

Chicago Conference

Sep 25 - Sep 26, 2015

Dallas Conference

Apr 10 - Apr 11, 2015